Escalera, AlbaRojo Fernández, AmayaRombauts, AlexanderAbelenda Alonso, GabrielaCarratalà, JordiGarcía Sastre, AdolfoAydillo, Teresa2024-07-012024-07-012024-03-012589-0042https://hdl.handle.net/2445/214055Despite multiple research efforts to characterize coronavirus disease 2019 (COVID-19) in humans, there is no clear data on the specific role of mucosal immunity on COVID-19 disease. Here, we longitudinally profile the antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and seasonal HCoV-OC43 S proteins in serum and nasopharyngeal swabs from COVID-19 patients. Results showed that specific antibody responses against SARS-CoV-2 and HCoV-OC43 S proteins can be detected in the upper respiratory tract. We found that COVID-19 patients mounted a robust mucosal antibody response against SARS-CoV-2 S with specific secretory immunoglobulin A (sIgA), IgA, IgG, and IgM antibody subtypes detected in the nasal swabs. Additionally, COVID-19 patients showed IgG, IgA, and sIgA responses against HCoV-OC43 S in the local mucosa, whereas no specific IgM was detected. Interestingly, mucosal antibody titers against SARS-CoV-2 peaked at day 7, whereas HCoV-OC43 titers peaked earlier at day 3 post -recruitment, suggesting an immune memory recall to conserved epitopes of beta-HCoVs in the upper respiratory tract.13 p.application/pdfengcc by-nc-nd (c) Escalera, Alba et al, 2024http://creativecommons.org/licenses/by-nc-nd/3.0/es/SARS-CoV-2ImmunologiaSARS-CoV-2Immunologyinfo:eu-repo/semantics/article2024-06-14info:eu-repo/semantics/openAccess38433913